
Reporting adverse events is a critical element of a clinical trial zzso In 2003, the Consolidated zzso of Reporting Trials zzso group generated recommendations regarding the appropriate reporting of adverse zzso The degree to which these recommendations are followed in zzso publications has not been zzso zzso 

A review of citations from zzso zzso and zzso published between Jan 1, 2009 and December 31, 2011, identified eligible randomized, controlled phase III trials in zzso solid zzso Publications were assessed for 14 adverse zzso elements derived from the CONSORT harms extension zzso a zzso score zzso 0 to zzso was calculated by adding the number of elements zzso Linear zzso analysis identified which publication characteristics associated with reporting zzso 

A total of 175 publications, with data for zzso patients, were included in the zzso The median zzso score was eight zzso three to zzso Most publications zzso reported only adverse events occurring above a threshold rate or severity, 37% did not specify the criteria used to select which adverse events were reported, and zzso grouped together adverse events of varying zzso zzso analysis revealed that trials without a stated funding source and with an earlier year of publication had significantly lower zzso zzso 

Reporting of adverse events in zzso publications of zzso trials is zzso and characterized by substantial selectivity and zzso The development of zzso standards for adverse event reporting should be established to ensure consistency and provide critical information required for medical zzso 

